Volume 16 Supplement 3

Sepsis 2012

Open Access

LPS-induced Pellino3 degradation is mediated by p62-dependent autophagy

  • A Heeg1,
  • L Kuchler1,
  • LK Eifler1,
  • T Knape2,
  • H Heide3,
  • B Brüne1 and
  • A von Knethen1
Critical Care201216(Suppl 3):P50

DOI: 10.1186/cc11737

Published: 14 November 2012


In macrophages Toll-like receptor 4 (TLR4) is activated in response to lipopolysaccharide (LPS) and induces proinflammatory cytokine expression [1]. Therefore, mechanisms terminating proinflammatory gene expression are important. Autophagy plays a central role in controlling innate immune responses by lysosomal degradation of signaling proteins, thus contributing to the resolution of inflammation [2]. Autophagic proteins like p62 directly interact with molecules involved in the TLR4-signaling pathway, but a correlation with the IRAK E3 ligase and scaffold protein Pellino3 remains obscure [3, 4]. Hence, we are interested in elucidating the function of Pellino3 to prove our hypothesis that it is a key regulator in the TLR4-signaling cascade [5].


We used the cecal ligation and puncture (CLP) mouse model causing polymicrobial sepsis to analyze Pellino3 protein and mRNA expression. Furthermore, we induced endotoxemia in RAW264.7 mouse macrophages by LPS treatment to verify in vivo experiments. Lentiviral Pellino3 knockdown in RAW264.7 macrophages was used for cytokine measurements at mRNA level. To analyze potential Pellino3 binding partners in TLR4-signaling by mass spectrometry (MS), we overexpressed FLAG-tagged Pellino3 in RAW264.7 macrophages, treated cells for 3, 6 and 24 hours with LPS and immunoprecipitated Pellino3 via its FLAG-tag. To consider Pellino3 degradation as a result of p62-mediated autophagy, we transiently knocked down p62 by siRNA in RAW264.7 macrophages and also pharmacologically blocked LPS-induced autophagy by Bafilomycin A1.


We demonstrated Pellino3 protein degradation in primary CD11b+ splenocytes after 24 hours following CLP operation and confirmed this in RAW264.7 macrophages after 24-hour LPS stimulation. Knockdown of Pellino3 attenuates proinflammatory cytokines, for example IL-6 mRNA, after 6 hours of LPS. Furthermore, we found by MS and verifying immunoprecipitation experiments that p62 is a Pellino3 binding partner, thus targeting Pellino3 for degradation. In line, both p62 knockdown and Bafilomycin A1 treatment prevent Pellino3 degradation, supporting an autophagic mechanism.


Our observations highlight a regulatory role of Pellino3 on TLR4 signaling. Thus, antagonism of Pellino3 in the hyperinflammatory phase of sepsis may counteract the cytokine storm. Furthermore, stabilization of Pellino3 by inhibition of autophagy in the hypoinflammatory phase of sepsis may improve immunity. In consideration of these two conflictive sepsis phases, modulation of Pellino3 may provide a new strategy for the development of a therapy approach in sepsis.



This research was supported by a grant from the Deutsche Forschungsgemeinschaft (KN493/9-1 and SFB TP3).

Authors’ Affiliations

Institute of Biochemistry I - Pathobiochemistry, Goethe-University Frankfurt
Fraunhofer IME Project Group - Translational Medicine and Pharmacology
Molecular Bioenergetics - Centre of Biological Chemistry, Goethe-University


  1. Zhu J, Mohan C: Toll-like receptor signaling pathways - therapeutic opportunities. Mediators Inflamm 2010, 2010: 781235.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Xu Y, Liu XD, Gong X, Eissa NT: Signaling pathway of autophagy associated with innate immunity. Autophagy 2008, 4: 110-112.View ArticlePubMedGoogle Scholar
  3. Levine B, Mizushima N, Virgin HW: Autophagy in immunity and inflammation. Nature 2011, 469: 323-335. 10.1038/nature09782PubMed CentralView ArticlePubMedGoogle Scholar
  4. Schauvliege R, Janssens S, Beyaert R: Pellino proteins are more than scaffold proteins in TLR/IL-1R signalling: a role as novel RING E3-ubiquitin-ligases. FEBS Lett 2006, 580: 4697-4702. 10.1016/j.febslet.2006.07.046View ArticlePubMedGoogle Scholar
  5. Hennessy EJ, Parker AE, O'Neill LA: Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 2010, 9: 293-307. 10.1038/nrd3203View ArticlePubMedGoogle Scholar


© Heeg et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.